Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XueBiJing in critically ill cardiovascular surgery patients
NCT04993794Unknown
- Sponsor
- Nanjing Medical University
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Randomised, double-blind trial of xuebijing in acute kidney injury (AKI) and Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by Nanjing Medical University. Primary endpoint: 28-day mortality. Status: unknown.
02
Drugs
xuebijing
03
Conditions
acute kidney injury (AKI)Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT04993794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993794.